Abstract
Relevance. Endometrial cancer ranks first among oncogynecological diseases, however, 5-year survival can be achieved only in 67,7 % of patients, while 22,4 % of patients die during this period from the continuation of the tumor process. Therefore, improving the complex therapy of patients with EC is very important.
 Purpose of the study. to investigate therapeutic pathomorphosis in patients with advanced endometrial cancer with neoadjuvantchemoradiation therapy.
 Materials and methods. In order to study radiation pathomorphosis, 26 patients with ER T1-3N0-1M0-1 were examined. Group I consisted of 11 patients with a preoperative course of external radiation therapy SOD 30 Gywithout radiomodification, II – 15 patients with a preoperative course of external radiation therapy SOD 30 Gywith radiomodification.
 Results and its discussion. When conducting a comparative assessment of radiation pathomorphism in patients of the study groups, it was found that when using the preoperative course of TFD on Gy 30 with radiomodification, a significant decrease in the mitotic index occurs. There is also a tendency to an increase in the degree of tumor regression, the number of pathological mitoses and stromal reactions during the preoperative course of TFD on 30 Gywith radiomodification.
 Conclusions. It was found that radiation therapy with EС with radiomodification gives a more positive effect and regression of more than 50,0 % of the tumor volume, a decrease in its biological potential. The volume of the damaged tumor was 58,0 %, and the volume of the residual tumor was 42,0 %, that is, most of the tumor mass underwent regression.
Highlights
Over the past two decades, Ukraine has experienced an increase in the incidence of endometrial cancer (EС), which, according to the Bulletin of the National Chancellor of the Register of Ukraine, currently accounts for 28 cases per 100,000 of the female population (26.4 in 2007) while the mortality rate indicator reached 6.8 per 100,000 female in 2008 [1, 2].The annual mortality due to cancer of this localization in Ukraine is about 2,000 females; in the USA it reaches 5,500, in Great Britain it is 750
The outcomes provided in table 6 show that the highest degree of radiation damage was observed in tumors with invasion of the myometrium of 0.5 cm and less
Histological grade of a tumor: in adenocarcinomas with moderate and low differentiation degree, the regression degree is moderate while pronounced dystrophic changes are typical for low-grade adenocarcinoma and rare forms;
Summary
Over the past two decades, Ukraine has experienced an increase in the incidence of endometrial cancer (EС), which, according to the Bulletin of the National Chancellor of the Register of Ukraine, currently accounts for 28 cases per 100,000 of the female population (26.4 in 2007) while the mortality rate indicator reached 6.8 per 100,000 female in 2008 [1, 2].The annual mortality due to cancer of this localization in Ukraine is about 2,000 females; in the USA it reaches 5,500, in Great Britain it is 750. According to the summary of the International Federation of Obstetricians and Gynecologists, five-year survival with EС досягти тільки в 67,7 % пролікованих хворих, тоді як 22,4 % пацієнток гинуть за такий же строк спостереження від рецидивів і метастазів пухлини [3, 4]. Оцінка результатів лікування РЕ свідчить про високу ефективність комбінованої терапії при ранніх стадіях захворювання, що дозволяє досягти п’ятирічної виживаності у 85–95 % хворих із І стадією процесу, у 65–70 % – із ІІ і лише у 29 % – із III стадією. Аналіз частоти розвитку рецидивів і метастазів РЕ залежно від їх локалізації показав, що у хворих, які лікуються комбінованим методом, рецидиви захворювання частіше спостерігалися на вагінальному рубці (6,4 %), метастази частіше виявлялися у піхві (2,7 %), в периферичних лімфатичних вузлах (3,2 %), у черевній порожнині (4,8 %) і легенях (3,7 %) [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
